$0.99
+0.00 (+0.35%)
Open$1.04
Previous Close$0.99
Day High$1.04
Day Low$0.98
52W High$7.54
52W Low$0.95
Volume—
Avg Volume104.6K
Market Cap5.89M
P/E Ratio—
EPS$-3.10
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+1,895.1% upside
Current
$0.99
$0.99
Target
$19.72
$19.72
$18.07
$19.72 avg
$32.84
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 850.6K | 846.2K | 822.4K |
| Net Income | -189,460 | -228,334 | -201,883 |
| Profit Margin | -22.3% | -27.0% | -24.6% |
| EBITDA | -320,116 | -324,230 | -315,475 |
| Free Cash Flow | -189,627 | -182,540 | -129,892 |
| Rev Growth | +3.9% | -4.1% | +22.7% |
| Debt/Equity | 0.68 | 0.61 | 0.74 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |